Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment.
| Title: | Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. |
|---|---|
| Authors: | Teleanu RI; 'Victor Gomoiu' Clinical Children's Hospital, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.; Chircov C; Faculty of Engineering in Foreign Languages, 060042 Bucharest, Romania.; Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Grumezescu AM; Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Teleanu DM; Emergency University Hospital, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania. |
| Source: | Journal of clinical medicine [J Clin Med] 2019 Dec 29; Vol. 9 (1). Date of Electronic Publication: 2019 Dec 29. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI AG, [2012]- |
| Abstract: | Angiogenesis is the process through which novel blood vessels are formed from pre-existing ones and it is involved in both physiological and pathological processes of the body. Furthermore, tumor angiogenesis is a crucial factor associated with tumor growth, progression, and metastasis. In this manner, there has been a great interest in the development of anti-angiogenesis strategies that could inhibit tumor vascularization. Conventional approaches comprise the administration of anti-angiogenic drugs that target and block the activity of proangiogenic factors. However, as their efficacy is still a matter of debate, novel strategies have been focusing on combining anti-angiogenic agents with chemotherapy or immunotherapy. Moreover, nanotechnology has also been investigated for the potential of nanomaterials to target and release anti-angiogenic drugs at specific sites. The aim of this paper is to review the mechanisms involved in angiogenesis and tumor vascularization and provide an overview of the recent trends in anti-angiogenic strategies for cancer therapy. |
| References: | Cancer Res. 2016 Apr 1;76(7):1673-4. (PMID: 27197239); Nat Rev Clin Oncol. 2018 May;15(5):325-340. (PMID: 29508855); J Investig Med. 2016 Feb;64(2):361-3. (PMID: 25955799); Int J Mol Sci. 2018 Apr 27;19(5):. (PMID: 29702562); Oncol Res Treat. 2018;41(4):164. (PMID: 29587285); Int J Mol Sci. 2019 Jan 31;20(3):. (PMID: 30709025); J Res Med Sci. 2017 Oct 31;22:117. (PMID: 29184575); Onco Targets Ther. 2018 Oct 17;11:6901-6909. (PMID: 30410348); J Clin Oncol. 2009 Oct 20;27(30):4966-72. (PMID: 19720913); Oncotarget. 2016 Aug 30;7(35):57197-57212. (PMID: 27527865); Oncol Res Treat. 2018;41(4):166-171. (PMID: 29562226); Heart Fail Rev. 2017 Nov;22(6):665-683. (PMID: 28639006); Biomed Rep. 2017 Dec;7(6):495-503. (PMID: 29188052); J Clin Oncol. 2014 May 1;32(13):1302-8. (PMID: 24637997); Biomedicines. 2017 Jun 21;5(2):. (PMID: 28635679); Cancer Metastasis Rev. 2017 Jun;36(2):249-262. (PMID: 28681240); J Cancer Res Ther. 2018 Apr-Jun;14(3):495-502. (PMID: 29893305); Int J Mol Sci. 2018 Apr 24;19(5):. (PMID: 29695053); Future Sci OA. 2018 Jun 28;4(7):FSO318. (PMID: 30112188); Int J Mol Sci. 2018 Jun 24;19(7):. (PMID: 29937525); Nat Rev Clin Oncol. 2018 May;15(5):310-324. (PMID: 29434333); Oncol Lett. 2018 Jul;16(1):687-702. (PMID: 29963134); Microvasc Res. 2018 May;117:1-9. (PMID: 29247718); J Endocrinol Invest. 2016 Nov;39(11):1235-1246. (PMID: 27344309); Handb Clin Neurol. 2016;135:253-274. (PMID: 27432670); Genes Cancer. 2010 Jan;1(1):12-25. (PMID: 21779425); J Clin Oncol. 2010 Jul 10;28(20):3239-47. (PMID: 20498403); Sci Transl Med. 2017 Apr 12;9(385):. (PMID: 28404866); Front Oncol. 2014 Apr 08;4:69. (PMID: 24782982); Nat Rev Cancer. 2017 Aug;17(8):457-474. (PMID: 28706266); Biochim Biophys Acta. 2006 Apr;1765(2):178-88. (PMID: 16406676); Iran J Public Health. 2019 Apr;48(4):713-721. (PMID: 31110982); Oncotarget. 2017 Jul 08;8(45):79703-79711. (PMID: 29108350); Adv Drug Deliv Rev. 2016 Feb 1;97:156-73. (PMID: 26518982); Mater Sci Eng C Mater Biol Appl. 2019 Apr;97:994-1008. (PMID: 30678987); Handb Clin Neurol. 2016;134:251-66. (PMID: 26948359); Cell Microbiol. 2012 Sep;14(9):1376-90. (PMID: 22507661); Front Pediatr. 2015 Apr 24;3:33. (PMID: 25964891); Pharmacol Rev. 2015;67(2):441-61. (PMID: 25769965); J Thorac Oncol. 2017 Feb;12(2):194-207. (PMID: 27729297); Rom J Morphol Embryol. 2018;59(2):455-467. (PMID: 30173249); Theranostics. 2018 Jan 1;8(2):533-548. (PMID: 29290825); Int J Mol Sci. 2017 Sep 14;18(9):. (PMID: 28906427); J Theor Biol. 2018 Dec 14;459:1-17. (PMID: 30240579); Curr Opin Nephrol Hypertens. 2016 Sep;25(5):404-9. (PMID: 27367910); Prog Mol Biol Transl Sci. 2015;135:227-57. (PMID: 26477917); Biosens Bioelectron. 2018 Jul 1;110:23-37. (PMID: 29579646); Surv Ophthalmol. 2016 Nov - Dec;61(6):759-768. (PMID: 27045225); Oncotarget. 2017 Jun 27;8(41):69577-69593. (PMID: 29050226); Vascul Pharmacol. 2019 Jan;112:91-101. (PMID: 30342234); Chemother Res Pract. 2012;2012:282570. (PMID: 23320169); Esophagus. 2018 Apr;15(2):53-58. (PMID: 29892930); Cells Tissues Organs. 2017;203(3):141-152. (PMID: 27654624); Curr Opin Pharmacol. 2018 Apr;39:60-67. (PMID: 29529399); Semin Cancer Biol. 2019 Jun;56:87-99. (PMID: 29128510); Nature. 2017 Apr 13;544(7649):250-254. (PMID: 28371798); Sci China Life Sci. 2018 Apr;61(4):380-391. (PMID: 29607461); J Clin Med. 2019 Nov 14;8(11):. (PMID: 31739580); Handb Exp Pharmacol. 2017;243:355-369. (PMID: 27718060); Mol Cancer. 2019 Mar 30;18(1):60. (PMID: 30925919); Cancer Manag Res. 2019 Apr 23;11:3469-3479. (PMID: 31114380); Taiwan J Obstet Gynecol. 2017 Apr;56(2):127-132. (PMID: 28420494); Nanoscale. 2018 Mar 28;10(12):5393-5423. (PMID: 29528075); Mol Aspects Med. 2018 Aug;62:12-21. (PMID: 28965749); Cancer Res. 2012 Apr 15;72(8):1909-14. (PMID: 22508695); Adv Clin Chem. 2019;88:1-33. (PMID: 30612603); Cancers (Basel). 2019 Mar 18;11(3):. (PMID: 30889903); PLoS One. 2017 Jun 8;12(6):e0179202. (PMID: 28594907); Int J Nanomedicine. 2019 Jul 11;14:5135-5146. (PMID: 31371952); J Cell Physiol. 2019 May;234(5):5700-5721. (PMID: 30378106); J Am Soc Nephrol. 2017 Jul;28(7):1973-1982. (PMID: 28465380); Br J Haematol. 2018 Feb;180(3):321-334. (PMID: 29076133); BMC Cancer. 2018 Oct 11;18(1):967. (PMID: 30305062); Cold Spring Harb Perspect Med. 2012 May;2(5):a006627. (PMID: 22553494); Clin Exp Nephrol. 2016 Jun;20(3):371-8. (PMID: 26676905); Lancet Oncol. 2018 Sep;19(9):1239-1246. (PMID: 30082170); Trends Biotechnol. 2016 Sep;34(9):733-745. (PMID: 27032730); F1000Res. 2016 Aug 25;5:. (PMID: 27635236); J Biol Chem. 2017 Mar 10;292(10):4054-4063. (PMID: 28115521); Adv Pharmacol. 2017;78:323-350. (PMID: 28212800); FASEB J. 2019 Jan;33(1):34-48. (PMID: 30085886); Curr Vasc Pharmacol. 2012 Sep;10(5):570-7. (PMID: 22338572); Mediators Inflamm. 2017;2017:4708076. (PMID: 28163397); Front Bioeng Biotechnol. 2018 Feb 12;6:7. (PMID: 29484295); Hypertens Res. 2016 Apr;39(4):183-91. (PMID: 26631852); Future Cardiol. 2016 Sep;12(5):585-99. (PMID: 27420190); Diabetologia. 2016 Aug;59(8):1616-20. (PMID: 27207083); Cancer Cell Int. 2017 Oct 30;17:89. (PMID: 29118670); Biomed Res Int. 2015;2015:549412. (PMID: 26146622); Methods Enzymol. 2014;548:23-67. (PMID: 25399641); Thromb Res. 2010 Apr;125(4):292-6. (PMID: 20004006); Int J Mol Sci. 2019 Jan 18;20(2):. (PMID: 30669338); Compr Physiol. 2017 Dec 12;8(1):153-235. (PMID: 29357127); Biomolecules. 2018 Jan 04;8(1):. (PMID: 29300337); Nanoscale. 2016 Jul 7;8(25):12444-70. (PMID: 27067119); Gynecol Oncol. 2015 Oct;139(1):10-6. (PMID: 26271155); J Clin Oncol. 2011 Apr 1;29(10):1252-60. (PMID: 21383283); PLoS Comput Biol. 2017 Sep 18;13(9):e1005724. (PMID: 28922358); Cancer Manag Res. 2018 Oct 03;10:4163-4172. (PMID: 30323672); Thorac Cancer. 2019 Jan;10(1):17-23. (PMID: 30411854) |
| Contributed Indexing: | Keywords: angiogenesis; anti-angiogenesis strategies; blood vessels; cancer; chemotherapy; immunotherapy; nanomaterials; nanotechnology; tumor |
| Entry Date(s): | Date Created: 20200108 Latest Revision: 20231113 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7020037 |
| DOI: | 10.3390/jcm9010084 |
| PMID: | 31905724 |
| Database: | MEDLINE |
Journal Article; Review